ZGNX News and Press, Zogenix Inc. From 10/26/20

EMERYVILLE, Calif., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the three and nine months ended September 30, 2020 and host a corporate upd...

Shares of Zogenix have been under pressure lately due to safety concerns surrounding its unique anti-epileptic drug, Fintepla. Despite receiving FDA approval for a rare and serious epileptic condition, Dravet syndrome, investors are concerned the drug's safety profile will limit its m...

Translate Bio reports positive early data for COVID-19 vaccine. Eli Lilly hits a roadblock for its COVID-19 antibody trial. Zogenix receives positive CHMP opinion for Dravet Syndrome treatment. For further details see: Translate's Covid-Vaccine, And Other News: The Good,...

The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending the marketing authorization of Zogenix's (ZGNX) FINTEPLA (fenfluramine) oral solution for the treatment of seizures associated with Dravet syndrome, a rare infant and child...

Dravet syndrome is a rare , life-long, infant- and childhood- onset epilepsy associated with severe, treatment-resistant seizures CHMP positive opinion based on Phase 3 study data that demonstrat e d FINTEPLA ® significant...

Zogenix (ZGNX) adds new analyses for FINTEPLA® (fenfluramine) oral solution in Dravet syndrome. Dravet syndrome is a rare, highly refractory form of infant- and childhood-onset epilepsy marked by frequent and often prolonged seizures that are difficult to control with existing medic...

Interim d ata from open-label extension trial show ed substantial seizure reduction s were maintained in patients treated with FINTEPLA® for up to two years Post-hoc analysis demonstrate d NNTs (Num...

EMERYVILLE, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that the initial purchasers of the previously announced offering of its 2.75% convertible senior notes due 2027 in a priv...

EMERYVILLE, Calif., Oct. 02, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, and its subsidiary Modis Therapeutics, shared new data and information about MT1621, the company’s investigati...

Thesis that FDA approval of Fintepla would immediately unlock value was wrong. With ZGNX down nearly 40% since, and the story still fully intact, the stock is now highly attractive. The recent $200M convertible debt deal surprised many. This large capital raise, on top of the $399...